

# **Is sickle cell disease a risk factor for severe COVID-19 : a multicenter national retrospective cohort**

**Short title:** Sickle cell disease and COVID-19

Abdulkarim Abdulrahman<sup>1,2</sup>, Mohammed Wael<sup>3</sup>, Fajer AlAmmadi<sup>4</sup>, Zahra AlMosawi<sup>4</sup>, Reem Alsherooqi<sup>4</sup>, Manal AlSayed<sup>5</sup>, Nitya Kumar<sup>6</sup>, Manaf AlQahtani<sup>1,5,6\*</sup>

<sup>1</sup> National Taskforce for Combating the Coronavirus (COVID-19), Bahrain

<sup>2</sup> Mohammed Bin Khalifa Cardiac Centre, Bahrain

<sup>3</sup> King Hamad University Hospital, Bahrain

<sup>4</sup> Ministry of Health, Bahrain

<sup>5</sup> Bahrain Defence Force hospital, Bahrain

<sup>6</sup> Royal College of Surgeons in Ireland, Bahrain

\*Corresponding author: Manaf AlQahtani.

Email: [mqahtani@rcsi-mub.com](mailto:mqahtani@rcsi-mub.com)

Phone: +973 3976 6000

Word count: 3353

Abstract Word count: 293

Tables: 6

Figures: 0

## Abstract

### Introduction

Coronavirus disease (COVID-19) caused by the novel coronavirus SARS-CoV-2 is an infectious disease which has evolved into a worldwide pandemic. Growing evidence suggests that individuals with pre-existing comorbidities are at higher risk of a more serious COVID-19 illness. Sickle cell disease (SCD) is an inherited hemoglobinopathy which increases the susceptibility to infections and as a consequent has higher risks of morbidity and mortality.

The impact of COVID-19 on SCD patients could lead to further increase in disease severity and mortality. Studies that examine the effect of SCD on COVID-19 outcomes are lacking. This study aims to determine whether SCD is a risk factor for severe COVID-19 infection in regards to the requirement of non-invasive ventilation/high flow nasal cannula (NIV/HFNC), mechanical intubation (MV) or death.

### Methods:

Retrospective cohort study which included COVID-19 patients admitted to four Ministry of Health COVID-19 treatment facilities in Bahrain during the period of 24, February 2020, to 31, July 2020. All SCD patients with COVID-19 were included and compared to randomly selected non-SCD patients with COVID-19. Data for the selected patients were collected from the medical records. Multivariate logistic regression models were used to control for confounders and estimate the effect of SCD on the outcomes.

### Results:

A total of 1,792 patients with COVID-19 were included; 38 of whom were diagnosed with SCD as well. In the SCD group, one (2.6%) patient required NIV/HFNC, one (2.6%) required MV and one (2.6%) death occurred. In comparison, 56 (3.2%) of the non-SCD patients required NIV/HFNC, 47 (2.7%) required MV and death occurred in 58 (3.3%) patients. Upon adjusting for confounders, SCD had an odds ratio of 1.847 (95% CI: 0.39 – 8.83;  $p=0.442$ ).

### Conclusion:

Our results indicate that SCD is not a risk factor for worse disease outcomes in COVID-19 patients.

**Keywords:** Sickle cell disease ; sickle cell ; COVID-19 ; Sars-CoV2; Corona virus ; Hemoglobinopathies ; Bahrain

## Introduction

The first case of the novel Coronavirus (SARS-CoV-2) was diagnosed in Wuhan, China in December 2019. Since then, the virus has spread drastically causing a pandemic that resulted in more than 81 million cases to date and more than 1.7 million deaths worldwide<sup>1</sup>. This led to global health and economic crises in multiple countries, many of which are projected to face long-lasting repercussions<sup>2</sup>.

The illness caused by the SARS-CoV-2 virus varies in its symptomatology and can range from being asymptomatic<sup>3</sup> to severe illness leading to acute respiratory distress syndrome and eventually, death<sup>4</sup>. Several studies have shown an association between higher rates of hospitalization and severe illness with advanced age, male gender, heart failure, diabetes mellitus, severe asthma, high body mass index, chronic kidney disease, chronic pulmonary disease and malignancy<sup>5-8</sup>. Additional factors that are suggestive of more serious COVID-19 complications include admission oxygen saturation of <88%, troponin-I level >1 ng/mL, C-reactive protein level >200 mg/L, and D-dimer levels >2500 ng/mL<sup>6</sup>. COVID-19 has been shown to increase the risk of thromboembolism which can lead to significant morbidity and mortality<sup>9</sup>.

Sickle cell disease (SCD) is an inherited group of disorders characterized by the presence of Hemoglobin S (HbS), either from homozygosity for the sickle mutation in the beta globin chain of hemoglobin (HbSS) or from compound heterozygosity of a sickle beta globin mutation with another beta globin mutation (e.g., Sickle-Beta Thalassemia). Hemoglobinopathies, sickle cell disease in particular, are commonly found in the Kingdom of Bahrain<sup>10</sup>. In 1995, a large study involving the hospitalized population of Bahrain which included 5,503 neonates and 50,695 non-neonates, reported the prevalence of SCD as 2.1% and HbS trait as 18.1% in neonates, and 10.4 % SCD in non-neonatal patients<sup>11</sup>.

A hereditary blood disorder prevention awareness campaign was started in 1985 which drastically reduced the incidence of hereditary blood disorders in Bahrain<sup>12</sup>. In May 2007,

newborn screening for SCD and thalassemia was established<sup>13</sup>. The program was offered to all newborns, where cord blood was tested for hemoglobinopathies. A total of 38,940 newborns were screened between 2007 and 2010. The incidence of SCD in newborns was found to be 0.7%, 0.6% and 0.4% in the years 2008, 2009 and 2010 respectively in comparison to 2.1% in 1985<sup>12</sup>.

Patients with SCD are at a higher risk of morbidity & mortality. As per the nature of the disease, they are predisposed to developing thrombotic events. These include vaso-occlusive crises, cerebrovascular accidents, acute sickle hepatic crises, acute hepatic sequestration and renal disease. Hemolytic crises, aplastic crises, infective episodes and priapism are also amongst the complications seen in these patients. This can explain why such patients tend to have a reduced life expectancy when compared to the general population<sup>14,15</sup>. Severe complications such as acute chest syndrome<sup>16</sup> and multiple organ failure<sup>17</sup> might be catastrophic and eventually lead to death.

Mortality rates for SCD patients admitted to intensive care units in Bahrain were 12.7%. This was slightly less than the overall mortality in other centers worldwide which was 17.2%.<sup>18</sup>

Critically ill patients can develop cytokine storm, progressive endothelial activation and disseminated intravascular coagulation (DIC) resulting in multi-organ failure<sup>19</sup>.

Patients with SCD often have multiple comorbidities including chronic lung disease. Viral infection can trigger acute vaso-occlusive crises in SCD patients, especially acute chest syndrome which is associated with high mortality rates<sup>20</sup>. In this setting of multi-organ dysfunction, in particular chronic lung damage, COVID-19 could easily trigger ACS and multi-organ failure. Underlying endothelial dysfunction and abnormal expression of procoagulants such as tissue factor could also place SCD patients at a greater risk<sup>21</sup>.

Hence, the combination of COVID-19 and SCD is hypothesized to cause an increase in disease severity and mortality. Studies that examine the effect of SCD on COVID-19 outcomes are lacking. Given the morbidity and mortality associated with sickle cell disease patients, it is predicted that these patients might have unfavorable outcomes when infected with the SARS-Cov-2 virus.

This study aims to determine if SCD is a risk factor for severe COVID-19 through comparing severity and outcomes of COVID-19 cases.

### Objectives :

1. Compare the odds of non-invasive ventilation, intubation or death in SCD cases and controls
2. Compare the odds of requiring oxygenation on presentation or admission in SCD cases versus controls

## **METHODS**

### **Study design and setting**

The study cohort included COVID-19 patients admitted to Bahrain's Ministry of Health COVID-19 treatment facilities during 24 February 2020 till 31 July 2020. The four participating institutions included: Ebrahim bin Khalil Kanoo COVID-19 Centre, Salmaniya Medical Complex COVID-19 Centre, Hereditary Blood Disorder Centre (HBDC) COVID-19 Centre and Jidhafs COVID-19 Centre. All SCD patients diagnosed with COVID-19 were included. Patients without SCD were sampled randomly from this COVID-19 study cohort.

### **Outcomes**

Primary outcome: The primary endpoint was the requirement of non-invasive ventilation, intubation or death.

Secondary outcome: The requirement for oxygenation on presentation or admission

## **Diagnosis**

The following methods were used to diagnose COVID-19 and sickle cell disease in our study

COVID-19: All patients were confirmed to be infected by SARS-CoV-2 using a PCR test of a nasopharyngeal sample. The PCR test was conducted using Thermo Fisher Scientific (Waltham, MA) TaqPath 1-Step RT-qPCR Master Mix, CG on the Applied Biosystems (Foster City, CA) 7500 Fast Dx RealTime PCR Instrument. The assay used and targeted the E gene. If the E gene was detected, the sample was then confirmed by RdRP and N genes. The E gene Ct value was reported and used in this study. Ct values >40 were considered negative. Positive and negative controls were included for quality control purposes.

Sickle Cell Disease: SCD status of patients was obtained from the medical records. All patients marked as SCD within the study time frame were included. Patients with sickle cell trait were not considered as SCD. The diagnosis of SCD is made through hemoglobin electrophoresis and confirmed by a positive sickling test result.

## **Patient Selection**

A full list of COVID-19 patients in these study periods and their SCD status were extracted from the electronic medical records. The list was imported into the statistical package. All COVID-19 patients with SCD as indicated in the EMR, were included. A total of 1850 non-SCD patients with COVID-19 were randomly sampled. Ninety-six patients were excluded due to duplicates, non hospitalized or due to lack of data. Data was collected for a total of 1754 patients.

## **Data sources and variables assessed**

We obtained data from the national electronic medical records database in Bahrain, “I-SEHA” . Since this EMR database stores information as unstructured data, the study

participants' information was manually extracted by five physicians, assisted by ten senior medical students. This team reviewed all the cases and collated the information into a structured dataset for this study. The data gathered included patients' demographic details, vital signs, laboratory test results, medication lists, past medical history, SCD status, clinical severity scale (as seen in the supplementary table attached in the appendix), oxygenation requirement on admission, the ratio of the oxygen saturation to the fraction of inspired oxygen (SpO<sub>2</sub>:FiO<sub>2</sub>) at admission, requirement of ventilator use and outcomes.

### **Statistical analysis**

The distribution of treatment groups was summarized. Bivariate associations between the sickle cell status groups and the measured patient characteristics were analyzed using Chi-squared ( $\chi^2$ ) tests for categorical variables and t-test for continuous variables. We assessed endpoints and their associations with both groups.

Multivariable logistic regression models were used to estimate the relationships between SCD and the composite primary and secondary endpoints. These models included demographic factors, clinical factors and medications.

The STATA software, version 15.1, was used to execute the statistical analyses, (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC.).

### **Ethical approval**

The protocol and manuscript for this study were reviewed and approved by the National COVID-19 Research Committee in Bahrain. This committee has been jointly established by the Bahrain Ministry of Health and Bahrain Defence Force Hospital research committees in response to the pandemic, to facilitate and monitor COVID-19 research in Bahrain. All methods and retrospective analysis of data was approved by the National COVID-19 Research and Ethics Committee, and carried out in accordance

with the local guideline and ethical guidelines of the Declaration of Helsinki 1975. All data used in this study was collected as part of normal medical procedures.

Informed consent was waived by the National COVID-19 Research and Ethics Committee for this study due to its retrospective and observational nature and the absence of any patient identifying information.

## **Results**

1792 cases were included. During the study period from 24<sup>th</sup> of February 2020 until 31<sup>st</sup> of July 2020; a total of 38 patients diagnosed with Sickle Cell Disease (SCD) were admitted with SARS Cov-2 infection. The outcomes of these patients were compared to a randomly selected control group of 1754 patients diagnosed with SARS Cov-2 during the same study period. There were a number of significant differences between the two groups (Table 1, 2, 3). The mean age of the SCD group was 35.5 years in comparison to 46.2 in the non-SCD group. 28.9% of the SCD group were males while 59.6% were males in the non-SCD group. All the SCD cases were Bahraini nationals, compared to 55.7% in the non-SCD group. Mean age, proportion of males, Bahraini nationals and G6PD deficiency status were significantly different in SCD cases and non-cases. It was also evident that diabetes and hypertension were more common in the control group. In the SCD group, 13.2% were diabetic compared to 29.2% in the non-SCD group, similarly, 13.2% of the SCD cases were hypertensive compared to 30.1% of the non-SCD group. On the other hand, G6PD deficiency was more prevalent within the SCD group (44.7%) while only 9% of the non-SCD patients had this deficiency. All these differences were statistically significant with p-value <0.05. The prevalence of cardiovascular disease was similar across both groups (10% and 10.5%).

Results also demonstrated that patients who had SCD had additional comorbidities. In the SCD group, 44.7% were diagnosed with at least one other comorbidity and 13.2% had three or more other co-morbidities in contrast to the 24.1% and 10.4% respectively in the non-SCD group.

The characteristics of the studied sample are summarized in Tables 1 to 3

Among the 33 (71.1%) of the symptomatic SCD patients, cough was the most common symptom (47.4%), followed by fever (42.1%). On the other hand, 1108 (63.2%) of non-SCD patients were symptomatic with similar common symptoms of cough (41.9%) and fever (21.9%).

Of the SCD group, 33 (89.2%) patients were admitted on room air, and 4 (10.8%) patients were admitted with oxygen support. None of the SCD patients admitted required further support on admission. Among the non-SCD patients, 1542 (87.9%) were admitted on room air, 201 (11.5%) on oxygen support, 8 (0.5%) on NIV/HFNC and 3 (0.2%) required mechanical ventilation (MV).

#### Disease outcomes:

In the SCD group, one (2.6%) patient required NIV/HFNC, one (2.6%) required MV and one (2.6%) death occurred. In comparison, 56 (3.2%) of the non-SCD patients required NIV/HFNC, 47 (2.7%) required MV and mortality was seen in 58 (3.3%). The outcomes are summarized in Table 4.

#### Primary outcome

The primary outcome of the study is to evaluate the composite outcome of the requirement for ventilation (invasive or noninvasive) or death or mortality (Table 5). The total number of patients who developed the primary outcome in both groups is 112/1792 (6.3%), of which 3/38 (7.9%) were in the SCD group and 109/1754 (6.2%) in the non-SCD group. The unadjusted odds ratio for SCD patients developing the primary outcome was 1.29 (95% CI: 0.39 – 4.27;  $p=0.67$ ). Upon adjusting for confounders, we found the odds ratio to be 2.06 (95% CI: 0.43 – 9.95;  $p= 0.37$ ). Table 5 summarizes these.

#### Secondary outcome

The secondary outcome of the study was the requirement of oxygenation on presentation (Table 6). The total number of patients who required oxygenation upon presentation was 12.1% (216/1792), of which 7.9% (4/38) were from the SCD group and 12.1% (212/1754) were from the non-SCD group. The unadjusted odds ratio was found to be 0.85 (95% CI: 0.30 – 2.44,  $p=0.77$ ). The adjusted odds ratio was found to be 1.39 (95% CI: 0.41 – 4.6;  $p= 0.59$ ).

Complete output and additional details on the models are available in the Appendix.

## Discussion

In this cohort study, SCD was not observed to be significantly associated with developing the primary composite outcome (requirement of NIV/HFNC/MV or death) in COVID-19 patients. SCD patients also did not have significantly higher odds of requiring oxygenation upon admission to the hospital as compared to non-SCD patients.

Upon analyzing the baseline characteristics of both groups, it was evident that there were significant differences in multiple domains. The non-SCD population was on average older than the SCD group. The younger mean age in SCD patients can be explained by the nature of the disease resulting in a reduced life expectancy<sup>22</sup>. Age has been reported to be associated with severe disease progression in COVID-19<sup>23</sup>. Most studies referred to age more than 60 years to increase the risk of worse outcomes. A study aiming to quantify the isolated effect of age on the severity of COVID-19 outcomes concluded a minimal influence after adjusting for important age-dependent risk factors (for example: diabetes, hypertension, cardiovascular disease etc.)<sup>24</sup>. On that account, although our study showed a difference of 10 years between the two groups, this might not have an actual effect on disease outcomes (since mean age was 46 and 35 years in the non-SCD and SCD groups, respectively). Regardless, age was adjusted for in the analysis conducted in this study.

All SCD patients were Bahraini nationals, compared to 55% of the patients in the non-SCD group. SCD is a genetic disorder that affects around 75,000 Bahrainis<sup>11,25</sup>. Bahrain

has a wide range of nationalities and around 50% of Bahrain's population comprises expatriate workers (with the majority being from Asian nationalities)<sup>25</sup>. SCD is a very rare disease within these countries<sup>26,27</sup> and hence this can explain the nationality difference observed. In addition, the majority of expatriate workers are male majority<sup>25</sup> and this accounted for the male predominance observed in the non-SCD group. Moreover this difference in gender distribution can be explained by the increased female prevalence of COVID-19 patients with hemoglobinopathies. A multicenter study by *de Sanctis et al*<sup>28</sup> and another study by *Panepinto et al*<sup>29</sup> established increased female prevalence (76.9% and 57% respectively) of COVID-19 infection among patients with hemoglobinopathies.

Among the comorbidities evaluated in all patients with COVID-19, results demonstrated that almost half of those with SCD were found to have G6PD deficiency in contrast to a minority in the control group. Some studies claim that G6PD deficiency incidence is more abundant in patients with SCD in comparison to the general population<sup>30</sup>. In addition, many studies have established the association of such inherited diseases due to the high rates of consanguineous marriages in the gulf region<sup>31</sup>. Further research on G6PD and COVID-19 outcomes is required to understand more on the topic.

On a different note, patients in the non-SCD group were found to be mostly comorbid with diabetes mellitus (DM) and hypertension (HTN), this could be attributed to the older age of the population<sup>32</sup>. The higher prevalence of DM and HTN increased the baseline risk of the non-SCD group to develop severe COVID-19 outcomes<sup>5-7</sup>.

One of the remarkable findings in this study was the significant variation in symptom presentation. Although the majority of patients in both groups did present with cough, SCD patients presented more expressively with fever. This may be attributed to the natural history of the disease where it creates an environment supporting infections<sup>33</sup>, although the presence of other causes of fever were not explored in this study.

COVID-19 infection has a broad clinical presentation; ranging from asymptomatic to severe forms of respiratory disease which can lead to death<sup>34</sup>. Few studies have been published studying the correlation between SCD and the severity of COVID-19 infection. A study by *Panepinto et al*<sup>29</sup> explored COVID-19 disease outcome in SCD patients living in the United States during the period March – May 2020. It concluded that this group of patients had increased risk of severe disease outcome as well as an increased mortality with 69% hospitalization rate, 11% ICU admission rate and 7% mortality rate. These were higher when compared to COVID-19 outcomes in the general population from a similar time period where hospitalization rate was 14%, ICU admission rate 2.3% and mortality rate 5.4%<sup>35</sup>.

Moreover, within the United States African American community, COVID-19 patients with SCD had higher rates of death from COVID-19 than those without SCD, as reported by Lana Mucalo et al at the American Society of Hematology (ASH) virtual meeting. Their study indicated that this population had 6.2 times the risk for COVID-19-related mortality<sup>36</sup>.

Another study, however, by Ashima Singh et al, indicated that African American individuals with SCD had similar risk of COVID-19-related mortality as those without SCD, after balancing for age, gender and other pre-existing conditions. Their study did report that SCD imposes additional risk of severe COVID-19 illness and hospitalization<sup>37</sup>.

In our study, SCD patients diagnosed with COVID-19 infection did not have a significant increase in risk for worse disease outcomes in comparison to the non-SCD patients. Similarly, SCD patients with COVID-19 did not have increased risk for requirement of oxygenation upon admission as compared those without SCD.

We have previously reported the disease outcomes in a case series of all SCD patients infected with COVID-19 between February and April 2020 in Bahrain. Six patients with SCD had COVID-19: three remained asymptomatic; two had mild symptoms and only one patient required oxygen support. The SCD patients had a similar average length of

stay when compared with non-SCD COVID-19 patients<sup>38</sup>. Other studies also showed similar results. *Chakravotry et al*<sup>39</sup> explored COVID-19 disease outcomes of 10 SCD patients in a tertiary hospital in the United Kingdom. The study demonstrated that most patients had mild disease with 80% not requiring oxygen and the remaining 20% requiring only a nasal cannula. Only one mortality case was described in a 54-year old female that had severe pre-existing lung disease and history of previous admissions to the intensive therapy unit within the past year. Likewise, *Faiz A et al*<sup>40</sup> presented a case series of four SCD patients diagnosed with COVID-19 infection. Three cases had mild disease and only one patient required oxygenation. All cases were discharged without mortalities.

Another case series by *Ramachandran et al* established low morbidity and mortality with COVID-19 in SCD patients. Among the nine SCD patients, only one required ICU admission but without the need for intubation. All cases were discharged and no deaths were observed<sup>41</sup>.

It is important to consider the sample used for this study as it represents hospitalized cases only. It is possible that other SCD patients remained in home isolation and did not require hospitalization and hence not included. Nevertheless, this would have not affected the results of this study. If these cases were included, the results would have moved more towards the null hypothesis.

## **STRENGTHS**

The study has several strengths; it involved the majority of hospitals that provided acute care for hospitalized COVID-19 cases in Bahrain. Furthermore, our study included all SCD cases admitted in the study time period allocated at the involved centres. The data collection process was done manually, hence, all patients' files were reviewed carefully and all documented details were collected. The study represents the only study conducted in the region to explore the relationship between SCD and COVID-19.

## **LIMITATIONS**

Since the study includes severe COVID-19 disease patients requiring hospitalization, inference on milder COVID-19 infections cannot be drawn from these results. Secondly, given the retrospective design, information that was not documented in EMR and was not available for analysis, could be potential confounders. These included: time from symptom onset, inflammatory markers and frequency of admission of SCD patients. This research did not study other relevant outcomes related to sickle cell disease including hemolysis, vaso-occlusive crisis, and other SCD crises. The genotype of sickle cell disease patient was not stratified as data on that wasn't readily available.

## **CONCLUSION**

Our results showed no significant increased risk of adverse COVID-19 outcome in SCD patients as compared to non-SCD patients. Further studies on this topic are warranted in order to have conclusive evidence on SCD and the risk of COVID-19 outcomes.

## References:

1. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. Accessed December 29, 2020. <https://coronavirus.jhu.edu/map.html>
2. Global Economic Prospects. World Bank. Accessed December 29, 2020. <https://www.worldbank.org/en/publication/global-economic-prospects>
3. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. *Ann Intern Med*. 2020;173(5):362-367. doi:10.7326/M20-3012
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet Lond Engl*. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
5. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775
6. Ej W, Aj W, K B, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4
7. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. *PLOS Med*. 2020;17(9):e1003321. doi:10.1371/journal.pmed.1003321
8. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. *Cancer Discov*. 2020;10(6):783-791. doi:10.1158/2159-8290.CD-20-0422
9. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. *EClinicalMedicine*. 2020;29. doi:10.1016/j.eclinm.2020.100639
10. El-Hazmi MAF, Al-Hazmi AM, Warsy AS. Sickle cell disease in Middle East Arab countries. *Indian J Med Res*. 2011;134(5):597. doi:10.4103/0971-5916.90984
11. Al Arrayed SS, Haites N. Features of sickle-cell disease in Bahrain. Published online 1995. Accessed December 29, 2020. <https://apps.who.int/iris/handle/10665/117239>
12. Al Arrayed S, Al Hajeri A. Newborn Screening Services in Bahrain between 1985 and 2010. *Adv Hematol*. 2012;2012:903219. doi:10.1155/2012/903219

13. User S. IthaMaps. Accessed December 29, 2020.  
<https://www.ithanet.eu/db/ithamaps>
14. Brozović M, Davies SC, Brownell AI. Acute admissions of patients with sickle cell disease who live in Britain. *Br Med J Clin Res Ed*. 1987;294(6581):1206-1208.  
doi:10.1136/bmj.294.6581.1206
15. Simon E, Long B, Koyfman A. Emergency Medicine Management of Sickle Cell Disease Complications: An Evidence-Based Update. *J Emerg Med*. 2016;51(4):370-381. doi:10.1016/j.jemermed.2016.05.042
16. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. *Blood*. 1997;89(5):1787-1792.
17. Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. *Am J Med*. 1994;96(2):155-162. doi:10.1016/0002-9343(94)90136-8
18. Al Khawaja SA, Ateya ZM, Al Hammam RA. Predictors of mortality in adults with Sickle cell disease admitted to intensive care unit in Bahrain. *J Crit Care*. 2017;42:238-242. doi:10.1016/j.jcrc.2017.07.032
19. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180(7):934-943.  
doi:10.1001/jamainternmed.2020.0994
20. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease. *N Engl J Med*. 2000;342(25):1855-1865.  
doi:10.1056/NEJM200006223422502
21. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. *J Thromb Haemost*. 2020;18(7):1559-1561.  
doi:https://doi.org/10.1111/jth.14849
22. Lubeck D, Agodoa I, Bhakta N, et al. Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. *JAMA Netw Open*. 2019;2(11).  
doi:10.1001/jamanetworkopen.2019.15374
23. Liu Y, Mao B, Liang S, et al. Association between age and clinical characteristics and outcomes of COVID-19. *Eur Respir J*. 2020;55(5).  
doi:10.1183/13993003.01112-2020
24. Romero Starke K, Petereit-Haack G, Schubert M, et al. The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis,

- and Meta-Regression. *Int J Environ Res Public Health*. 2020;17(16).  
doi:10.3390/ijerph17165974
25. Population and Demographics – Ministry of Information Affairs | Kingdom of Bahrain. Accessed December 29, 2020. <https://www.mia.gov.bh/kingdom-of-bahrain/population-and-demographics/?lang=en>
  26. Gorakshakar AC. Epidemiology of Sickle Hemoglobin in India. :6.
  27. Ahmed S, Saleem M, Modell B, Petrou M. Screening Extended Families for Genetic Hemoglobin Disorders in Pakistan.  
<http://dx.doi.org/10.1056/NEJMsa013234>. doi:10.1056/NEJMsa013234
  28. de Sanctis V, Canatan D, Corrons JLV, et al. Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study. *Mediterr J Hematol Infect Dis*. 2020;12(1). doi:10.4084/MJHID.2020.046
  29. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20–May 21, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC.  
doi:10.3201/eid2610.202792
  30. Antwi-Baffour S, Adjei JK, Forson PO, Akakpo S, Kyeremeh R, Seidu MA. Comorbidity of Glucose-6-Phosphate Dehydrogenase Deficiency and Sickle Cell Disease Exert Significant Effect on RBC Indices. Anemia.  
doi:<https://doi.org/10.1155/2019/3179173>
  31. Abdulhadi S. Association between genetic inbreeding and disease mortality and morbidity in Saudi population. *J Investig Genomics*. 2018;5.  
doi:10.15406/jig.2018.05.00069
  32. Nayak BS, Sobrian A, Latiff K, et al. The association of age, gender, ethnicity, family history, obesity and hypertension with type 2 diabetes mellitus in Trinidad. *Diabetes Metab Syndr*. 2014;8(2):91-95. doi:10.1016/j.dsx.2014.04.018
  33. Cannas G, Merazga S, Viroit E. Sickle Cell Disease and Infections in High- and Low-Income Countries. *Mediterr J Hematol Infect Dis*. 2019;11(1).  
doi:10.4084/MJHID.2019.042
  34. Piroth L, Cottenet J, Mariet A-S, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. *Lancet Respir Med*. 2020;0(0).  
doi:10.1016/S2213-2600(20)30527-0
  35. Stokes EK. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69.  
doi:10.15585/mmwr.mm6924e2

36. Mucalo L. Hospitalization and Case Fatality in Individuals with Sickle Cell Disease and COVID-19 Infection. In: ASH; 2020. Accessed December 30, 2020. <https://ash.confex.com/ash/2020/webprogram/Paper137676.html>
37. Singh A. COVID-19 Outcomes in Individuals with Sickle Cell Disease and Sickle Cell Trait Compared to Blacks without Sickle Cell Disease or Trait. In: ASH; 2020. Accessed December 30, 2020. <https://ash.confex.com/ash/2020/webprogram/Paper136763.html>
38. AbdulRahman A, AIAli S, Yaghi O, et al. COVID-19 and sickle cell disease in Bahrain. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020;101:14-16. doi:10.1016/j.ijid.2020.09.1433
39. Chakravorty S, Padmore-Payne G, Ike F, et al. COVID-19 in patients with sickle cell disease – a case series from a UK tertiary hospital. *Haematologica*. 2020;105(11). doi:10.3324/haematol.2020.254250
40. Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell disease. *Br J Haematol*. 2020;189(5):851-852. doi:<https://doi.org/10.1111/bjh.16734>
41. Ramachandran P, Perisetti A, Kathirvelu B, et al. Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience. *eJHaem*. 2020;1(2):608-614. doi:<https://doi.org/10.1002/jha2.87>

## **Acknowledgements:**

We would like to express our gratitude towards our colleagues: Abdulla AlAwadhi, Marwa AlMadhi, Islam AlSayed, Jumana AlAayed, Sara Jaafar Mohammed, Aesha Khalid Sharif, Khadija Alansari, Ammar Kheyami, Mujtaba Mal Alla, Abdulla AlMuharraqi, Zeyad Mahmood, Narjis Ali AlSheala, Ola Husain AlHalwachi, Maryam Ghazi Alarayedh, and Amna Mohamed Buheiji who played an essential role in the data collection process related to this paper. Our thanks and appreciation goes to them for their dedication and hard work and we wish them all the best in the future. We thank all the participants of the study and hope they will lead a long healthy life. We extend our condolences to the families of the lives lost due to COVID-19.

## **Disclosures**

Conflict of interest: The authors have declared that no conflict of interest exists.

Ethics approval and consent to participate: The study was approved by the National COVID-19 Research and Ethics Committee.

Consent for publication: All authors gave their consent for publication.

Availability of data and materials: All the data for this study will be made available upon reasonable request to the corresponding author.

Funding: No funding was received to perform this study.

Author contributions: AA, MQ gathered the data and supervised the data collection team. AA and NK analyzed and interpreted the data. AA, FA, MW, RS, ZM, wrote the manuscript. MQ, MA, NK edited the manuscript. All authors reviewed and approved the final version of the manuscript. MQ is the guarantor of this work.

Corresponding author:

Manaf AlQahtani

Email: [mqahtani@rcsi-mub.com](mailto:mqahtani@rcsi-mub.com)

Phone: +973 39766000

## Tables

### Table Legend

Table 1: Baseline characteristics of non-SCD and SCD groups

Table 2: Clinical characteristics of non-SCD and SCD groups

Table 3: COVID-19 related Medications received during hospital stay in non-SCD and SCD groups

Table 4: Outcomes in non-SCD and SCD groups

Table 5: Risks for developing the primary outcome

Table 6: Risks for developing the secondary outcome

Factor	Level	Non-SCD	SCD	p-value
N		1754	38	
Age – mean ± SD		46.2 ± 16.9	35.5 ± 18.7	<0.001
Male		1046 (59.6%)	11 (28.9%)	<0.001
Bahraini		977 (55.7%)	38 (100.0%)	<0.001
Presence of comorbidities (Other than SCD)	Yes	863 (49.2%)	22 (57.9%)	0.29
Number of comorbidities (Other than SCD)	0	891 (50.8%)	16 (42.1%)	0.005
	1	422 (24.1%)	17 (44.7%)	
	2	258 (14.7%)	0 (0.0%)	
	3+	183 (10.4%)	5 (13.2%)	
G6PD Deficiency		158 (9.0%)	17 (44.7%)	<0.001
Diabetes Mellitus		512 (29.2%)	5 (13.2%)	0.031
Cardiovascular Disease (CVD)		176 (10.0%)	4 (10.5%)	0.92
Hypertension		528 (30.1%)	5 (13.2%)	0.024
Asthma		78 (4.4%)	2 (5.3%)	0.81
Chronic Obstructive Pulmonary Disease (COPD)		7 (0.4%)	0 (0.0%)	0.70
Chronic Kidney Disease (CKD)		77 (4.4%)	2 (5.3%)	0.80
Other Chronic Lung Disease (not asthma nor COPD)		9 (0.5%)	0 (0.0%)	0.66

Table 1: baseline characteristics of non-SCD and SCD groups

Factor	Level	Non-SCD	SCD	p-value
Fever (>38C)		385 (21.9%)	16 (42.1%)	0.003
Cough		735 (41.9%)	18 (47.4%)	0.50
Chest Pain		153 (8.7%)	6 (15.8%)	0.13
Shortness of Breath		354 (20.2%)	6 (15.8%)	0.50
Loss of smell		53 (3.0%)	3 (7.9%)	0.088
Loss of taste		50 (2.9%)	4 (10.5%)	0.006
Diarrhea		101 (5.8%)	3 (7.9%)	0.58
Nausea or Vomiting		91 (5.2%)	2 (5.3%)	0.98
Body pain		266 (15.2%)	12 (31.6%)	0.006
Heart Rate on admission: bpm - mean $\pm$ SD		86.6 $\pm$ 14.2	91.8 $\pm$ 15.1	0.027
SBP on admission: mmHg - mean $\pm$ SD		130.6 $\pm$ 18.7	121.4 $\pm$ 15.0	0.004
DBP on admission: mmHg - mean $\pm$ SD		77.3 $\pm$ 11.7	70.9 $\pm$ 11.1	0.001
Respiratory rate on admission: breath per minute - mean $\pm$ SD		20.1 $\pm$ 6.9	20.2 $\pm$ 1.5	0.97
Elevated ALT>40U/L		398 (24.6%)	10 (27.8%)	0.66
Elevated Creatinine		166 (9.5%)	3 (7.9%)	0.74
CXR findings	Pneumonia	515 (34.4%)	16 (44.4%)	0.21
	Normal	981 (65.6%)	20 (55.6%)	
Hypotension (SBP<90mmHg or DBP<60mmHg) on admission		72 (4.1%)	5 (13.2%)	0.006
Tachypnea (RR>22) on admission		49 (2.8%)	0 (0.0%)	0.30
Disease severity on admission	On room air	1542 (87.9%)	33 (89.2%)	0.97
	On oxygen support (nasal cannula/ face mask)	201 (11.5%)	4 (10.8%)	
	On NIV/HFNC	8 (0.5%)	0 (0.0%)	
	Mechanical ventilation	3 (0.2%)	0 (0.0%)	
Oxygenation on admission		212 (12.1%)	4 (10.5%)	0.77

Table 2: clinical characteristics of non-SCD and SCD groups

Medication	Non-SCD	SCD	p-value
Hydroxychloroquine	531 (30.3%)	6 (15.8%)	0.054
Azithromycin	430 (24.5%)	15 (39.5%)	0.035
Kaletra	318 (18.1%)	6 (15.8%)	0.71
Ribavirin	267 (15.2%)	6 (15.8%)	0.92
Steroids	198 (11.3%)	6 (15.8%)	0.39
Tocilizumab	81 (4.6%)	1 (2.6%)	0.56
Convalescent Plasma Transfusion	65 (3.7%)	3 (7.9%)	0.18

Table 3: Medications received during hospital stay in non-SCD and SCD groups

Factor	Non-SCD	SCD	p-value
NIV/HFNC/MV or Death	109 (6.2%)	3 (7.9%)	0.67
NIV/HFNC	56 (3.2%)	1 (2.6%)	0.85
Intubation	47 (2.7%)	1 (2.6%)	0.99
Death	58 (3.3%)	1 (2.6%)	0.82

Table 4: Outcomes in non-SCD and SCD groups

Analysis	Ventilation or Death	p-value
No. of events/no. of patients at risk (%)	112/1792 (6.3%)	-
SCD	3/38 (7.9%)	-
Non-SCD	109/1754 (6.2%)	-
Crude analysis – odds ratio (95%CI)	1.29 (0.39 – 4.27)	0.67
Multivariable analysis* – odds ratio (95%CI)	1.847 (0.39 – 8.83)	0.442

\*covariates included were age, gender, hypertension, chronic kidney disease, severity scale on admission hydroxychloroquine, azithromycin, steroids, tocilizumab, plasma transfusion

Table 5: Risks for developing the primary outcome

Analysis	Oxygenation	p-value
No. of events/no. of patients at risk (%)	216/1792 (12.1%)	-
SCD	4/38 (7.9%)	-
Non-SCD	212/1754 (12.1%)	-
Crude analysis – odds ratio (95%CI)	0.85 (0.30 – 2.44)	0.77
Multivariable analysis* – odds ratio (95%CI)	1.39 (0.41 – 4.61)	0.59

\*covariates included were age, male, Bahraini nationality, hypertension, chronic kidney disease, COPD, symptoms, fever, cough shortness of breath, heart rate, diastolic blood pressure

Table 6: Risks for developing the secondary outcome